Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 10c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.08), $0.10 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.49 million versus the consensus estimate of $37.9 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Loop Capital Starts Chime Financial (CHYM) at Buy
• Barnes & Noble Education (BNED) Tops Q1 EPS by 12c